GPLD1 and ovarian cancer: We previously conducted a phase I study of the combination of CPT-11 and PLD in patients with platinum- and taxane-resistant recurrent ovarian cancer and reported that the recommended doses of CPT-11 and PLD were 80 and 30 mg/m2, respectively [6].